Evercore ISI Group says Novocure is still a good buy but has cut its price target from $23 to $20.

NVCR · Novocure Limited

The AI's read

This is an analyst's view, not a new report about Novocure's sales or treatment results. Keeping the Outperform rating points one way, but lowering the target points the other. The update does not clearly change the company's business outlook.